We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

000100:SSEYuhan Corporation Analysis

Data as of 2026-06-14 - not real-time

₩77,200.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Yuhan Corporation is trading at 77,200 KRW, well below its 20‑day (81,785), 50‑day (88,316) and 200‑day (106,725) simple moving averages, signaling a clear bearish price trend. Technical indicators such as an RSI of 38 and a negative MACD histogram reinforce the downside momentum, while the stock hovers near the identified support level of 71,700 KRW and faces resistance around 90,500 KRW. Fundamentally, the company posts a respectable 7.2% revenue growth but operates on thin margins (operating margin 1.7%) and carries an alarming debt‑to‑equity ratio of 15.3, despite holding a sizable cash buffer. The DCF‑derived fair value of roughly 24,030 KRW is dramatically lower than the market price, and a forward P/E of 28.2 exceeds the industry average of 24.8, indicating the stock is overvalued. Dividend yield is modest at 0.78% with a payout ratio of 21%, which appears sustainable given the cash reserves, yet free cash flow remains negative. High 30‑day volatility (≈44%) and a beta of 0.86 suggest the stock is prone to sharp moves, and the current “Extreme Greed” sentiment on the fear‑greed index adds a contrarian caution.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Price below all major SMAs
  • Negative MACD and RSI indicating oversold momentum
  • Proximity to support with high short‑term volatility

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Elevated debt‑to‑equity ratio limiting financial flexibility
  • Valuation gap between market price and DCF fair value
  • Steady dividend payout despite modest yield

Long Term

> 3 years
Positive
Model confidence: 5/10

Key Factors

  • Strong cash position to eventually deleverage
  • Long‑term growth prospects in specialty & generic pharma
  • Sustainable dividend offering a modest income stream

Key Metrics & Analysis

Financial Health

Revenue Growth7.20%
Profit Margin9.55%
P/E Ratio28.2
ROE8.90%
ROA2.15%
Debt/Equity15.31
Op. Cash Flow₩138.5B
Free Cash Flow₩-59860910080
Industry P/E24.8

Technical Analysis

TrendBearish
RSI38.1
Support₩71,700.00
Resistance₩90,500.00
MA 20₩81,785.00
MA 50₩88,316.00
MA 200₩106,725.00
MACDBearish
VolumeStable
Fear & Greed Index89.86

Valuation

Fair Value₩24,030.00
Target Price₩130,111.11
Upside/Downside68.54%
GradeOvervalued
TypeValue
Dividend Yield0.78%

Risk Assessment

Beta0.87
Volatility43.94%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.